search tools

Allergan's BELKYRA® (Deoxycholic Acid) Receives Marketing Authorisation In Sweden For The Treatment Of Moderate To Severe Fullness Under The Chin (Double Chin) (Allergan plc)

Edit Public Technologies 13 Oct 2016
(Source. Allergan plc). DUBLIN, Oct. 13, 2016 /PRNewswire/ -- Allergan plc (NYSE. AGN) a leading global pharmaceutical company, announced that Sweden has received the Marketing Authorisation for BELKYRA® (deoxycholic acid) after being granted approval by the Swedish Medical Products Agency (MPA) ... Logo - http.//photos.prnewswire.com/prnh/20150612/222796LOGO ... as KYBELLA® ... Journal of the European Academy of Dermatology and Venereology ... SKINmed....

Phase 3 results for Sun Pharma's investigational psoriasis medicine, tildrakizumab

Edit Topix 05 Oct 2016
Sun Pharma has announced late-breaking data from two pivotal Phase-3 clinical trials achieving the primary endpoint with tildrakizumab, an investigational IL-23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria. As indicated in a previous press release, top line results from these studies were announced on May 4, 2016 ... ....

Castle Creek Pharmaceuticals Announces Late-Breaking Results at EADV of Phase 2 Topical Diacerein 1% Data ...

Edit Business Wire 03 Oct 2016
The data were presented at the 25th Annual Congress of the European Academy of Dermatology and Venereology (EADV) in Vienna, Austria1 by Professor Johann Bauer, M.D., MBA HCM; Head of the Univ ... ....

TheraVida, Inc. Release: THVD-102 Demonstrates Promising Potential As ...

Edit Topix 03 Oct 2016
Positive Phase 2 study results with THVD-102, a combination drug product for the treatment of primary focal hyperhidrosis , or excessive sweating, were presented on October 1, 2016 at the 25th European Academy of Dermatology and Venereology Congress, in Vienna, Austria. David M ... ....

Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey (Novartis AG)

Edit Public Technologies 03 Oct 2016
People with the disease also report that they face discrimination, humiliation, and mental illness, according to the research presented at the European Academy of Dermatology and Venereology (EADV) Congress ... Presented at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress 2016 ... Presented at the 25th Annual European Academy of Dermatology and Venereology (EADV) Congress 2016....

Almirall to Announce Late-Breaking Results for Investigational IL-23p19 inhibitor, Tildrakizumab, Achieves Primary End Point in Both Phase-3 Studies in Patients with Moderate-to-Severe Plaque Psoriasis (Almirall SA)

Edit Public Technologies 03 Oct 2016
(Source. Almirall SA). Barcelona, 3 October 2016. Pivotal Data of the Targeted IL-23p19 Antibody Presented for the First Time at the 25th European Academy of Dermatology and Venereology (EADV) Congress ... Tildrakizumab clinical trials included over 1,800 patients from more than 200 clinical trial sites worldwide ... Prof ... and Europe are proceeding ... Presented as a late breaking abstract at the European Academy of Dermatology and Venereology 2016....

New Phase 3 Data Show Significant Efficacy Versus Placebo and Superiority of Guselkumab Versus Humira® In Treatment of Moderate to Severe Plaque Psoriasis (Johnson & Johnson)

Edit Public Technologies 03 Oct 2016
(Source. Johnson & Johnson) ... These data were presented for the first time at the 25 European Academy of Dermatology and Venereology (EADV) Congress and mark the first-ever results from a head-to-head study of an IL-23-targeted biologic therapy (guselkumab) compared with an anti-TNF-alpha treatment (adalimumab) ... Serious infections occurred in two patients receiving guselkumab and three patients receiving adalimumab ... About VOYAGE 1 ... ### ... ....

Sentinel Lymph Node Biopsy: Part of Melanoma Treatment's Exciting Future

Edit Topix 02 Oct 2016
Timothy M. Johnson, MD, spoke enthusiastically about the possibilities of sentinel lymph node biopsy in his lecture at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria. His presentation, called "Melanoma Sentinel Node Biopsy. Past, Present and Future in the New Era of Systemic Therapies," covered guidelines for the procedure as well as new possibilities for melanoma patients ... ....

Dermira Presents Data from DRM04 Phase 3 Clinical Program in...

Edit Topix 02 Oct 2016
... to improve the lives of patients with dermatologic diseases, today presented data, including new disease-related quality of life data, from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis in a late-breaking news session at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria....

Emerging Therapies and Future Considerations for Treating Moderate-to-Severe Atopic Dermatitis

Edit Topix 02 Oct 2016
The present and future of atopic dermatitis treatments was the focus of discussion this Saturday at the European Academy of Dermatology and Venereology Congress in Vienna, Austria, during a symposium sponsored by Sanofi Genzyme and Regeneron ... ....

The Benefits of Crisaborole for the Quality of Life of Patients With...

Edit Topix 01 Oct 2016
Thursday at the 25th European Academy of Dermatology and Venereology Congress in Vienna, Austria, 2 presentations focused on the effects of crisaborole topical ointment, 2%, in treating atopic dermatitis. This Thursday, at the 25th European Academy of Dermatology and Venereology Congress in Vienna, 2 presentations focused on the effects of crisaborole topical ointment, 2%, in treating atopic dermatitis ... ....

J&J; psoriasis drug tops placebo, Humira in late stage study

Edit The Himalayan 01 Oct 2016
An experimental biotech drug developed by Johnson & Johnson proved more effective at clearing moderate to severe cases of the skin condition plaque psoriasis than a placebo or Abbvie Inc’s big-selling Humira, according to data from a late stage study presented on Saturday ... The data was presented at the European Academy of Dermatology and Venereology (EADV) Congress in Vienna, Austria ... ....

J&J;’s Skin Drug Beats Humira in Final-Stage Psoriasis Study

Edit Bloomberg 01 Oct 2016
Johnson & Johnson’s experimental drug for psoriasis hit its main goals and outperformed a rival in a final-stage study, positioning the company to expand its arsenal of immune-disease treatments ... That compared with a 55 percent rate among those on AbbVie Inc.’s Humira, New Brunswick, New Jersey-based J&J said ... The data were presented Saturday at the European Academy of Dermatology and Venereology Congress in Vienna ... LEARN MORE. ....
×
×
×
×